Esophagectomy for cancer in octogenarians.
Because of changes in life expectancy, there is an increasing number of elderly patients with esophageal cancer. The aim of this study was to assess the outcome of esophagectomy for cancer in patients 80 years or older. A retrospective review was performed of the records of all patients who underwent esophagectomy for cancer from 1992 to 2007. A cardiac and pulmonary evaluation was obtained on an individual basis in the younger patients and in all octogenarians. Among 560 patients with esophagectomy for cancer, 47 patients (8%) were octogenarians. The median age of the younger group (n= 513) was 63 years (interquartile range 56-71). Octogenarians had significantly more stage III disease (49% vs 31%, P= 0.02) but received less neoadjuvant therapy than younger patients (2% vs 21%, P= 0.0004). In octogenarians, the transhiatal resection was more common than in the younger group (79% vs 36%, P < 0.0001). Weight loss prior to surgery was similar in both groups, but body mass index was significantly lower in octogenarians (25 vs 28 kg/m(2) , P= 0.0002). Major complications occurred in 26% in octogenarians and 31% in the younger group (P= 0.51). Hospital mortality was similar (9% for octogenarians vs 4% in the younger group, P= 0.13). The median postoperative hospital stay was similar at 16 days (P= 0.69). There was no difference in cancer-related survival (median survival 48.9 vs 59.3 months, P= 0.31 log-rank test). Esophagectomy can be performed safely in carefully selected octogenarians with good cardiac and pulmonary function. Patients should not be denied an esophagectomy based only on their age.
Zehetner
J
J
Department of Surgery, Keck School of Medicine, University of Southern California, Los Angeles, California, USA.
Lipham
J C
JC
Ayazi
S
S
Banki
F
F
Oezcelik
A
A
DeMeester
S R
SR
Hagen
J A
JA
DeMeester
T R
TR
D000230:Adenocarcinoma / Q000401:mortality / Q000473:pathology / Q000503:physiopathology* / Q000628:therapy*; D000367:Age Factors; D000368:Aged; D000369:Aged, 80 and over; D015992:Body Mass Index; D057186:Comparative Effectiveness Research; D004938:Esophageal Neoplasms / Q000401:mortality / Q000473:pathology / Q000503:physiopathology* / Q000628:therapy*; D016629:Esophagectomy / Q000009:adverse effects; D006334:Heart Function Tests; D006801:Humans; D017567:Karnofsky Performance Status; D008875:Middle Aged; D020360:Neoadjuvant Therapy / Q000009:adverse effects; D009367:Neoplasm Staging; D011183:Postoperative Complications; D012129:Respiratory Function Tests; D012189:Retrospective Studies; D015996:Survival Rate; D016896:Treatment Outcome